- Global Pharma News & Resources

Untargeted Lipidomics Now Available with Creative Proteomics’s New Cutting-Edge Lipidomics Platform

As a division of Creative Proteomics, Lipidomics is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomics services for biomedical research institutions, biotechnology companies, and pharmaceutical companies. The company has recently announced the fully-developed untargeted lipidomics service, which can analyze hundreds of different lipids simultaneously, and is widely used in cancer, diabetes, Alzheimer's disease, and cardiovascular disease research.


Lipidomics is the systematic study of all lipid molecules (> 30,000 species) within a biological system, tissue, fluid or cell. To better understand cellular physiology and pathophysiology, comprehensive identification and precise quantification of lipids is essential for lipidomic studies.


Untargeted lipidomics can analyze thousands of different lipids simultaneously, which is valuable for assessing an individual's health. Differences in lipid profiles have been widely used in the study of cancer, diabetes, Alzheimer's disease and cardiovascular disease. These massively detailed lipid profiles can be used to assess medical risk, monitor and optimize patient treatment and are the basis for the concept of precision medicine. Application areas of untargeted lipidomics include agricultural sciences, biomarkers, Alzheimer's disease, atherosclerosis, cardiovascular disease, cancer, diabetes and obesity research, clinical diagnostics, drug discovery and systems biology.


“Based on LC-MS/MS high-throughput analysis technology, we have established a untargeted lipidomics analysis platform to systematically analyze the research mode of lipid composition and expression changes in organisms. It can effectively study the changes and functions of lipid families and lipid molecules in various biological processes, and then elucidate the relevant life activity mechanisms,” commented Creative Proteomics’s senior scientist.


From the perspective of lipid research methods, many lipid analysis methods have been established. There are mainly thin-layer chromatography (TLC) methods, gas chromatography-mass spectrometer (GC-MS) methods, electrospray ionization mass spectrometry (ESI-MS) methods, and matrix assisted laser desorp-Uon /ionization-time of flight mass spectrometry (MALDITOF-MS) and nucIearmagnetic resonance (NMR) methods. The more advanced ESI-MS method can qualitatively and quantitatively analyze lipid molecular species, and has become a powerful tool for lipid analysis.


Application areas of Creative Proteomics’s untargeted lipidomics analysis platform:

  1. Identification of lipid substances in biological samples;
  2. Research on lipid function and metabolic regulation;
  3. Research on lipid metabolism pathway and network;
  4. Lipid biomarker discovery.


Melissa George, senior director of omics marketing of Creative Proteomics, said, “After years of technical accumulation, our platform is equipped with advanced instrumentation, including GC-MS, LC-MS, LC-MS/MS, shot-gun, MALDI-MS, etc. Creative Proteomics designs experimental plans according to customers' needs, selects different technical methods, improves detection efficiency, and ensures the accuracy and repeatability of experimental results. A detailed report is provided at the end of the entire project, including experimental procedures, MS/MS instrument parameters, raw data, and bioinformatics analysis to help you find differentiated lipid molecules.”


More information is available from the website:


About Creative Proteomics

Creative Proteomics has gradually grown into an integrated service provider with targeted lipidomics and untargeted lipidomics analysis services for researchers in pharmaceutical, biotechnology, agriculture, and nutrition industries, as well as academic and government organizations. With a continued focus on quality, Creative Proteomics is proud to meet our worldwide clients' needs.



Address: Shirley, NY 11967, USA



Editor Details

Last Updated: 27-Apr-2022